CYLERT
LOE ApproachingNDAORALTABLET, CHEWABLEPriority Review
Approved
Jan 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYLERT is an oral small-molecule tablet approved in 1976 for an unknown indication. The mechanism of action and pharmacologic class are not specified in available data. This legacy product represents a foundational asset in Abbott's portfolio with decades of clinical use.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely transitioning to defend market share or manage decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYLERT offers limited career growth opportunities given its mature, LOE-approaching lifecycle and zero linked job openings. Roles would focus on managed decline, generic transition planning, and market defense rather than expansion or innovation.
Brand ManagerCommercial Operations Analyst
Worked on CYLERT at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.